In Brief: Lilly's Gemzar
Executive Summary
EXCULPATIONS AND EXPLANATIONS: Lilly's Gemzar: Median survival for "clinical benefit responders" was 10.7 months for Gemzar patients compared to 4.8 months in Lilly's Phase II trial. "The Pink Sheet" (May 20, p. 6) was not clear about the population to whom this parameter pertained...